Erschienen in:
01.03.2011 | Original Paper
Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma
verfasst von:
Chel Hun Choi, Ji-Soo Lee, Seong Rim Kim, Yoo-Young Lee, Chul-Jung Kim, Jeong-Won Lee, Tae-Joong Kim, Je-Ho Lee, Byoung-Gie Kim, Duk-Soo Bae
Erschienen in:
Journal of Cancer Research and Clinical Oncology
|
Ausgabe 3/2011
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Eukaryotic translation initiation factor 4E (eIF4E) is overexpressed in many cancer and is emerging as a potential therapeutic target. Yet data on the expression of eIF4E in endometrial cancer are lacking.
Methods
Immunohistochemistry was used to evaluate the expression of eIF4E in 62 endometrial cancer surgical specimens. We subsequently evaluated whether inhibition of eIF4E by siRNA would have an impact on cell growth in endometrial cancer cell lines, using the MTT cell proliferation assay.
Results
According to a chosen cutoff value, 36 (58.1%) of 62 patient specimens scored as eIF4E positive. The positivity of eIF4E was significantly more frequent in tumors extending outside the uterus (stage III/IV vs. stage I/II, P = 0.027). Lastly, downregulation of eIF4E by siRNA reduced the growth of HEC-1A cells significantly but had a somewhat weaker effect in Ishikawa cells (P < 0.001).
Conclusions
Expressions of eIF4E correlated with prognosis of endometrial adenocarcinomas. Our results suggest that eIF4E might be a promising therapeutic target in endometrial cancer.